Company Overview of Syntaxin Ltd
Syntaxin Ltd., a biotechnology company, discovers and develops biopharmaceuticals that treat diseases through selective inhibition of cell secretory pathways. The company specializes in the design, recombinant expression, and purification of botulinum neurotoxins and targeted secretion inhibitors (TSIs). It develops TSIs for the treatment of a range of diseases, including endocrine, sensory and respiratory conditions, and oncology. The company was founded in 2005 and is based in Oxon, United Kingdom with an additional office in Abingdon, United Kingdom. As of July 15, 2013, Syntaxin Ltd. operates as a subsidiary of Ipsen S.A.
Units 4-10The Quadrant
Oxon, OX14 3YS
Founded in 2005
44 1235 552 100
44 1235 552 200
Key Executives for Syntaxin Ltd
Similar Private Companies By Industry
|ADC Biotechnology Ltd||Europe|
|Advanced Gel Technology Limited||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Syntaxin Ltd, please visit www.syntaxin.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.